Posted by Michael Wonder on 01 Mar 2018
Sorrento Therapeutics subsidiary, Scilex, receives US FDA approval for non-opioid ZTlido (lignocaine topical system) 1.8% for PHN pain
28 February 2018 - ZTlido uses novel technology demonstrating 12 hour wear for efficient lignocaine delivery, even during exercise.
Sorrento Therapeutics received approval from the U.S. FDA for ZTlido (lignocaine topical system) 1.8%. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.
In a separate Phase 1 comparative adhesion study in normal healthy subjects (n=44), ZTlido demonstrated superior adhesion (p <0.0001) to Lidoderm at 3 hours that improved over the 12-hour administration period.
